

Maria Laura Avantaggiati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10758999/publications.pdf>

Version: 2024-02-01

38
papers

8,085
citations

218592
26
h-index

330025
37
g-index

38
all docs

38
docs citations

38
times ranked

18195
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	Recruitment of p300/CBP in p53-Dependent Signal Pathways. <i>Cell</i> , 1997, 89, 1175-1184.	13.5	661
3	p300 and CBP: Partners for life and death. <i>Journal of Cellular Physiology</i> , 1999, 181, 218-230.	2.0	272
4	Acetylation of Androgen Receptor Enhances Coactivator Binding and Promotes Prostate Cancer Cell Growth. <i>Molecular and Cellular Biology</i> , 2003, 23, 8563-8575.	1.1	244
5	Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. <i>Journal of Cell Biology</i> , 2006, 173, 533-544.	2.3	239
6	Hormonal Control of Androgen Receptor Function through SIRT1. <i>Molecular and Cellular Biology</i> , 2006, 26, 8122-8135.	1.1	214
7	The tumor suppressor protein p53 is required for neurite outgrowth and axon regeneration. <i>EMBO Journal</i> , 2006, 25, 4084-4096.	3.5	203
8	The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. <i>Oncotarget</i> , 2012, 3, 1220-1235.	0.8	160
9	The 400 kDa Subunit of the PCAF Histone Acetylase Complex Belongs to the ATM Superfamily. <i>Molecular Cell</i> , 1998, 2, 869-875.	4.5	158
10	A key role of the mitochondrial citrate carrier (SLC25A1) in TNF α - and IFN γ -triggered inflammation. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2014, 1839, 1217-1225.	0.9	145
11	Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cMYC protooncogene at the transcriptional level. <i>Biochemical and Biophysical Research Communications</i> , 1991, 176, 985-992.	1.0	116
12	Dietary downregulation of mutant p53 levels via glucose restriction. <i>Cell Cycle</i> , 2012, 11, 4436-4446.	1.3	111
13	The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. <i>Cell Death and Differentiation</i> , 2018, 25, 1239-1258.	5.0	81
14	YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells. <i>Developmental Cell</i> , 2019, 49, 425-443.e9.	3.1	78
15	An Acetylation Switch Regulates SUMO-Dependent Protein Interaction Networks. <i>Molecular Cell</i> , 2012, 46, 759-770.	4.5	77
16	Dissecting the pathways that destabilize mutant p53: The proteasome or autophagy?. <i>Cell Cycle</i> , 2013, 12, 1022-1029.	1.3	70
17	SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker. <i>Oncotarget</i> , 2014, 5, 1212-1225.	0.8	68
18	Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. <i>Cell Death and Differentiation</i> , 2020, 27, 2143-2157.	5.0	60

#	ARTICLE	IF	CITATIONS
19	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. <i>Molecular Cancer Research</i> , 2019, 17, 1815-1827.	1.5	40
20	Characterization of the hepatitis B virus preS/S region encoded transcriptional transactivator. <i>Virology</i> , 1992, 187, 663-670.	1.1	38
21	Roles of p300, pocket proteins, and hTBP in E1A-mediated transcriptional regulation and inhibition of p53 transactivation activity. <i>Journal of Cellular Biochemistry</i> , 1997, 66, 277-285.	1.2	38
22	The Mitochondrial Citrate Carrier SLC25A1/CIC and the Fundamental Role of Citrate in Cancer, Inflammation and Beyond. <i>Biomolecules</i> , 2021, 11, 141.	1.8	36
23	The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. <i>Oncotarget</i> , 2014, 5, 10678-10691.	0.8	36
24	Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. <i>Journal of Cellular Physiology</i> , 2010, 225, 394-405.	2.0	33
25	An Intrinsically Disordered Region of the Acetyltransferase p300 with Similarity to Prion-Like Domains Plays a Role in Aggregation. <i>PLoS ONE</i> , 2012, 7, e48243.	1.1	30
26	p53 Modulates Notch Signaling in MCF7 Breast Cancer Cells by Associating With the Notch Transcriptional Complex Via MAML1. <i>Journal of Cellular Physiology</i> , 2015, 230, 3115-3127.	2.0	27
27	The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells. <i>Aging</i> , 2015, 7, 854-867.	1.4	25
28	Expanding the Clinical Spectrum of Mitochondrial Citrate Carrier (SLC25A1) Deficiency: Facial Dysmorphism in Siblings with Epileptic Encephalopathy and Combined D,L-2-Hydroxyglutaric Aciduria. <i>JIMD Reports</i> , 2014, 19, 111-115.	0.7	23
29	The mitochondrial aspartate/glutamate carrier isoform 1 gene expression is regulated by CREB in neuronal cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 60, 157-166.	1.2	21
30	Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells. <i>Cell Death and Differentiation</i> , 2020, 27, 2263-2279.	5.0	20
31	Functional mimicry of the acetylated C-terminal tail of p53 by a SUMO1 acetylated domain, SAD. <i>Journal of Cellular Physiology</i> , 2010, 225, 371-384.	2.0	18
32	VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. <i>Cancer Biology and Therapy</i> , 2010, 10, 320-325.	1.5	18
33	Dietary n-3 polyunsaturated fatty acids fail to reduce prostate tumorigenesis in the PB-ErbB-2 x Pten ^{+/-} preclinical mouse model. <i>Cell Cycle</i> , 2010, 9, 1824-1829.	1.3	13
34	The SLC25A1-p53 mutant crosstalk. <i>Aging</i> , 2015, 7, 519-520.	1.4	5
35	An expanded role for Caveolin-1 in brain tumors. <i>Cell Cycle</i> , 2013, 12, 1485-1486.	1.3	3
36	Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e140-e147.	1.1	2

#	ARTICLE	IF	CITATIONS
37	Cancer metabolism as a therapeutic target: finding the right target(s) in the context of tumor heterogeneity, evolution, and metabolic plasticity. <i>Oncology</i> , 2013, 27, 474, 476-7.	0.4	1
38	The AP1 Transcription Factor as a Model to Study the Modulation of Intracellular Signalling Pathways by the Hepatitis B Virus Transactivator pX. , 1994, , 748-752.		0